• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Galapagos NV

    10/8/24 4:35:06 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email
    SC 13D/A 1 tm2425722d1_sc13da.htm SC 13D/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

    (Amendment No. 1)*

    (Rule 13d-101)

     

    Information to be included in statements filed pursuant

    to § 240.13d-1(a) and amendments thereto filed

    pursuant to § 240.13d-2(a)

    Under the Securities Exchange Act of 1934

     

    Galapagos NV

    (Name of Issuer)

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    36315X101

    (CUSIP Number)

     

    Oleg Nodelman

    EcoR1 Capital, LLC

    357 Tehama Street #3

    San Francisco, CA 94103

    (415) 448-6534

     

    with a copy to

     

    Richard M. Brand

    Cadwalader, Wickersham & Taft LLP

    200 Liberty Street

    New York, NY 10281

    (212) 504-6000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    October 6, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

      1.

    Names of Reporting Persons

    EcoR1 Capital, LLC

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    AF

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    7,094,0491

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    7,094,0491

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,094,0491

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    10.77%*

      14.

    Type of Reporting Person (See Instructions)

    OO, IA

                      

    1 The amounts reported include (1) ordinary shares, no par value, of Galapagos NV (the “Issuer”) and (2) American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Issuer’s Form 20-F filed with the U.S. Securities and Exchange Commission on March 28, 2024 (the “Form 20-F”). 

     

     

     

     

      1.

    Names of Reporting Persons

    Oleg Nodelman

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    AF

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    7,094,0491

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    7,094,0491

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,094,0491

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    10.77%*

      14.

    Type of Reporting Person (See Instructions)

    IN

                      

    1 The amounts reported above include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Form 20-F.

     

     

     

     

      1.

    Names of Reporting Persons

    EcoR1 Capital Fund Qualified, L.P.

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    WC

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    6,674,7381

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    6,674,7381

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    6,674,7381

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    10.13%*

      14.

    Type of Reporting Person (See Instructions)

    PN

                      

    1 The amounts reported above include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Form 20-F.

     

     

     

     

      1.

    Names of Reporting Persons

    EcoR1 Capital Fund L.P.

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    WC

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    419,3111

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    419,3111

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    419,3111

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    0.64%*

      14.

    Type of Reporting Person (See Instructions)

    PN

                        

    1 The amounts reported above include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Form 20-F.

     

     

     

     

    Explanatory Note

     

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the Schedule 13D filed on August 23, 2024 to the extent set forth herein (as amended and supplemented through the date of this Amendment No. 1, collectively, the “Schedule 13D”) by the Reporting Persons, relating to the ordinary shares, no par value (the “Ordinary Shares”), and American Depositary Shares, each of which represents one ordinary share, no par value (the “ADSs”), of the Issuer (together, the “Shares”). Capitalized terms not otherwise defined in this Amendment No. 1 shall have the meaning ascribed to them in the Schedule 13D.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

     

    Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    All of the Shares reported herein were purchased by the Funds for an aggregate purchase price of $353,195,707.22 including fees and expenses, excluding fees with respect to the conversion of ADSs to Ordinary Shares. In connection with the surrender of certain ADSs held by the Funds and withdrawal of ordinary shares of the Issuer from Citibank, N.A., as depositary (the “Depositary” and such exchange, the “ADS Conversion”), the Funds paid $293,693.40 in fees to the Depositary. The source of funds used by the Funds to purchase such Shares and to effect the ADS Conversion was derived from the capital of the Funds.

     

    The response to Item 5 of the Schedule 13D is incorporated herein by reference. Unless noted above, no part of the purchase price for such Shares was borrowed by any Reporting Person for the purpose of acquiring, holding, trading or voting any securities discussed in this Item 3.

     

    Item 4.   Purpose of Transaction.

     

    Item 4 of the Schedule 13D is hereby amended and supplemented to add the following information to the end thereof:

     

    On October 6, 2024, the Board agreed to appoint Mr. Nodelman to the Board as a non-executive non-independent director, effective October 7, 2024, and to nominate and recommend Mr. Nodelman for appointment as director with a term of four years at the next meeting of shareholders of the Issuer.

     

    The response to Item 5 of the Schedule 13D is incorporated herein by reference.

     

    Item 5. Interest in Securities of the Issuer.

     

    Items 5(a), (b) and (c) of the Schedule 13D are hereby amended and restated in their entirety as follows:

     

    (a), (b) EcoR1 and Mr. Nodelman each may be deemed to beneficially own an aggregate of 7,094,049 Shares (the “Subject Shares”), representing approximately 10.77% of the outstanding Shares based on 65,897,071 Shares outstanding as of December 31, 2023, as reported in the Issuer’s Form 20-F. Qualified Fund may be deemed to beneficially own an aggregate of 6,674,738 of the Subject Shares, representing approximately 10.13% of the outstanding Shares. Capital Fund may be deemed to beneficially own an aggregate of 419,311 of the Subject Shares, representing approximately 0.64% of the outstanding Shares.

     

    EcoR1, as the general partner of each of the Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares. Mr. Nodelman may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares. Each of the Funds may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) only the Subject Shares that it beneficially owns.

     

     

     

     

    (c) Exhibit 99.2 filed herewith, which is incorporated by reference into this Item 5(c), describes the transactions in the Shares that were effected by the Reporting Persons since the Reporting Persons’ most recent filing on Schedule 13D.

     

     Pursuant to the terms of the Depositary Agreement dated May 4, 2015, between the Issuer and the Depositary, on September 10, 2024, EcoR1 caused the Funds to begin the ADS Conversion, pursuant to which Qualified Fund surrendered 5,526,088 ADSs to the Depositary and received in exchange 5,526,088 Ordinary Shares, and Capital Fund surrendered 347,780 ADSs to the Depositary and received in exchange 347,780 Ordinary Shares. The ADS Conversion exchange was completed on September 20, 2024.

     

    Except as set forth in Exhibit 99.2 filed herewith and other than the ADS Conversion, no transactions in the Shares were effected by the Reporting Persons since the Reporting Persons’ most recent filing on Schedule 13D.

     

    Item 7. Material to be Filed as Exhibits.

      

    Item 7 is hereby amended and supplemented to add the following exhibits:

     

    Exhibit 99.2Trading Data.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: October 8, 2024 EcoR1 CAPITAL, LLC
       
      By: /s/ Oleg Nodelman
        Name: Oleg Nodelman
        Title: Manager
       
    Date: October 8, 2024 OLEG NODELMAN
       
      By: /s/ Oleg Nodelman
        Oleg Nodelman
       
    Date: October 8, 2024 EcoR1 CAPITAL FUND QUALIFIED, L.P.
       
      By: EcoR1 Capital, LLC, General Partner
       
      By: /s/ Oleg Nodelman
        Name: Oleg Nodelman
        Title: Manager
       
    Date: October 8, 2024 EcoR1 CAPITAL FUND, L.P.
       
      By: EcoR1 Capital, LLC, General Partner
       
      By: /s/ Oleg Nodelman
        Name: Oleg Nodelman
        Title: Manager

     

     

    Get the next $GLPG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    8/24/2023Buy → Neutral
    Citigroup
    5/5/2023Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

      First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

      4/23/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Announces Executive Leadership Updates

      Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo  Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strategic guidance Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today makes two executive leadership announcements. In line with its planned separation

      4/21/25 4:10:00 PM ET
      $GLPG
      $NMRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

      Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. Mr. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Mr. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos' transformation into a cell therapy company. The company expects to announce Mr. Huston's successor in the coming months.Paul Stoffels1, MD, CEO and Chair of the B

      4/15/25 1:30:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Galapagos NV downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

      2/14/25 8:06:36 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos NV downgraded by Kepler

      Kepler downgraded Galapagos NV from Hold to Reduce

      11/20/24 7:41:53 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Galapagos NV with a new price target

      Leerink Partners initiated coverage of Galapagos NV with a rating of Market Perform and set a new price target of $24.00

      9/9/24 7:50:07 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    SEC Filings

    See more
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/29/25 4:44:24 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/23/25 5:19:27 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/21/25 5:30:59 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Financials

    Live finance-specific insights

    See more
    • Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

      First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

      4/23/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

      Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – G

      2/12/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

      Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncologyManagement to host conference call today at 14:00 CET / 8:00 am ET MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GL

      1/8/25 1:30:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Galapagos NV

      SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

      11/12/24 9:55:16 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Galapagos NV

      SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

      10/8/24 4:35:06 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Galapagos NV

      SC 13D - GALAPAGOS NV (0001421876) (Subject)

      8/23/24 4:01:26 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Leadership Updates

    Live Leadership Updates

    See more
    • Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

      Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company.  The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2024 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has the honor to invite its shareholders, holders of subscription rights, Board members, and

      3/27/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

      Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to accelerate innovation and create near-and long-term value.  "We are pleased to welcome Oleg Nodelman to the Galapagos Board," said Dr. Paul Stoffels, Galapagos' CEO and Chair of the Board of Direc

      10/7/24 1:00:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

      Publication of annual report for financial year 2023Annual Shareholders' Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders' Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders' Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of t

      3/28/24 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care